Predictive value of the ultrasensitive HIV viral load assay in clinical practice

Journal of Medical Virology

Volumn 61, Issue 4, 2000, Pages 411-416

  Muir, David ^a   White, David ^b   King, Julie ^a   Verlander, Neville ^c   Pillay, Deenan ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antiretrovirals; HIV RNA

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; VIRUS RNA;

ANTIMICROBIAL THERAPY; ARTICLE; ASSAY; CLINICAL PRACTICE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; STANDARD; SURVIVAL TIME; VIRUS DETECTION; VIRUS LOAD;

ANTI-HIV AGENTS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; VIRAL LOAD; VIREMIA;

EID: 0033922088     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200008)61:4<411::AID-JMV1>3.0.CO;2-M     Document Type: Article

References (19)

1. Ashcroft ME, Skidmore SJ, Olowokure B, Pillay D. 1998. Audit of HIV RNA quantitation measurements in the West Midlands: a preliminary report. Intl J STD AIDS 9:361-363.
2. BHIVA Writing Committee. 2000. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 1:76-101.
3. Bratt G, Karlasson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. 1998. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 12:2193-2202.
4. De Mendoza C, Perez-Olmeda M, Soriano V, Gonzalez-Lahoz J. 1998. 4th International Congress on drug therapy in HIV infection, Glasgow 1998. Rate of rebound in plasma viraemia and emergence of drug resistance at 1 year in patients achieving <50 copies/ml compared to those having 50-500 copies/ml at the 3rd month of being under HAART. Abstract P210. AIDS 12(Suppl 4):S69.
5. Erali M, Hillyard DR. 1999. Evaluation of the ultrasensitive Roche Amplicor HIV-1 Monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol 37:792-795.
6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739.
7. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337:725-733.
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
9. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT. 1997. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 126:929-938.
10. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J. 1996. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 10:167-173.
11. Lucas GM, Chaisson RE, Moore RD. 1999. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131:81-87.
12. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo Jr CR. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946-954.
13. O'Brien WA, Hatigan PM, Daar ES, Simberkoff MS, Hamilton JD. 1997. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 126:939-945.
14. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected comparments during combination therapy. Nature 387: 188-191.
15. Pilcher CD, Miller WC, Beatty ZA, Eron EJ. 1999. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy. AIDS 13:1337-1342.
16. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. 1999. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 13:1873-1880.
17. Raboud JM, Montaner SG, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D. 1998. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12: 1619-1624.
18. Sun R, Ku J, Jayakar H, Kuo JC, Brambilla D, Herman S, Rosenstraus M, Spadoro J. 1998. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 36:2964-2969.
19. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.